While no significant differences were observed in terms of degree of expanded disability status scale (EDSS) and MRI data, lenercept-treated patients experienced significant exacerbations, meaning the appearance of new symptoms, and neurological deficits tended to be more severe compared to placebo-group, indicating that TNF inhibition was deleterious in MS. This evidence concerns the gene TNF and myeloid sarcoma.